Literature DB >> 20044779

Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates.

Kosmas I Paraskevas, Alexandros A Tzovaras, Vassilios Stathopoulos, Dimitri P Mikhailidis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20044779     DOI： 10.1007/s11255-009-9677-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  20 in total

1.  Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease.

Authors:  K B Meyer; A S Levey
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

Review 2.  Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.

Authors:  Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2007-12-08       Impact factor: 2.370

3.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

4.  Left ventricular systolic and diastolic function and carotid intima-media thickness in pediatric dialysis patients.

Authors:  Mahmut Civilibal; Huseyin Oflaz; Salim Caliskan; Cengiz Candan; Nur Canpolat; Gulseren Pehlivan; Lale Sever; Ozgur Kasapcopur; Nil Arisoy
Journal:  Int Urol Nephrol       Date:  2008-08-09       Impact factor: 2.370

5.  Statins and vitamin D: a friendly association in pre-dialysis patients.

Authors:  Pedro L Neves; Anabela Malho; Ana Cabrita; Ana Pinho; Alexandre Baptista; Elsa Morgado; Marília Faísca; Hermínio Carrasqueira; Ana P Silva
Journal:  Int Urol Nephrol       Date:  2009-09-11       Impact factor: 2.370

6.  The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease.

Authors:  Fahed Youssef; Prakash Gupta; Alexander M Seifalian; Fiona Myint; Dimitri P Mikhailidis; George Hamilton
Journal:  Angiology       Date:  2004 Jan-Feb       Impact factor: 3.619

7.  Statins and renal function in patients with diabetes mellitus.

Authors:  Vasilios G Athyros; Athanasios A Papageorgiou; Moses Elisaf; Dimitri P Mikhailidis
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

8.  Chronic kidney disease stages 3-5 and cardiovascular disease in the veterans affairs population.

Authors:  Debasish Banerjee; Gabriel Contreras; Isabel Jaraba; Decio Carvalho; Luis Ortega; Cristiane Carvalho; Candido Pezon; Stephen P Rosenthal; Norman De La Rosa; Nuripama Vemuri; Gautam Cherla; Nilay Nahar
Journal:  Int Urol Nephrol       Date:  2009-01-01       Impact factor: 2.370

9.  Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Authors:  Vasilios G Athyros; Moses Elisaf; Athanasios A Papageorgiou; Athanasios N Symeonidis; Anthimos N Pehlivanidis; Vasilios I Bouloukos; Haralambos J Milionis; Dimitri P Mikhailidis
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  1 in total

1.  Twenty four-hour ambulatory blood pressure monitoring and lipid levels before, 3, 6 and 12 months after the onset of hemodialysis in chronic kidney disease patients: a pilot study.

Authors:  Ag Vagiona; Sa Koupidis; P Passadakis; El Thodis; V Vargemezis
Journal:  Hippokratia       Date:  2012-04       Impact factor: 0.471
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.